1. Home
  2. ALLT vs ALLO Comparison

ALLT vs ALLO Comparison

Compare ALLT & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALLT
  • ALLO
  • Stock Information
  • Founded
  • ALLT 1996
  • ALLO 2017
  • Country
  • ALLT Israel
  • ALLO United States
  • Employees
  • ALLT N/A
  • ALLO N/A
  • Industry
  • ALLT Telecommunications Equipment
  • ALLO Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • ALLT Telecommunications
  • ALLO Health Care
  • Exchange
  • ALLT Nasdaq
  • ALLO Nasdaq
  • Market Cap
  • ALLT 313.2M
  • ALLO 371.8M
  • IPO Year
  • ALLT 2006
  • ALLO 2018
  • Fundamental
  • Price
  • ALLT $8.73
  • ALLO $1.29
  • Analyst Decision
  • ALLT Buy
  • ALLO Strong Buy
  • Analyst Count
  • ALLT 1
  • ALLO 9
  • Target Price
  • ALLT $13.00
  • ALLO $8.44
  • AVG Volume (30 Days)
  • ALLT 475.0K
  • ALLO 3.8M
  • Earning Date
  • ALLT 05-12-2025
  • ALLO 05-13-2025
  • Dividend Yield
  • ALLT N/A
  • ALLO N/A
  • EPS Growth
  • ALLT N/A
  • ALLO N/A
  • EPS
  • ALLT N/A
  • ALLO N/A
  • Revenue
  • ALLT $93,455,000.00
  • ALLO N/A
  • Revenue This Year
  • ALLT $9.08
  • ALLO N/A
  • Revenue Next Year
  • ALLT $6.09
  • ALLO N/A
  • P/E Ratio
  • ALLT N/A
  • ALLO N/A
  • Revenue Growth
  • ALLT N/A
  • ALLO N/A
  • 52 Week Low
  • ALLT $2.02
  • ALLO $0.86
  • 52 Week High
  • ALLT $9.44
  • ALLO $3.78
  • Technical
  • Relative Strength Index (RSI)
  • ALLT 67.97
  • ALLO 52.12
  • Support Level
  • ALLT $8.02
  • ALLO $1.10
  • Resistance Level
  • ALLT $8.32
  • ALLO $1.15
  • Average True Range (ATR)
  • ALLT 0.40
  • ALLO 0.10
  • MACD
  • ALLT 0.02
  • ALLO 0.04
  • Stochastic Oscillator
  • ALLT 78.28
  • ALLO 77.14

About ALLT Allot Ltd.

Allot Ltd is a provider of network intelligence and security solutions for service providers and enterprises. The company's solutions are deployed globally for network and application analytics, traffic control and shaping, and network-based security services. The firm's multi-service platforms are deployed by mobile, fixed, and cloud service providers and enterprises. The company has a customer base in Europe, Asia and Oceania, the Americas, the Middle East, and Africa.

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

Share on Social Networks: